Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance

ABBOTT LABORATORIES

2025-Q1 EPS reported $0.76 revenue$10,358,000,000

GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).
Reported revenue $10.36B (+4.0%), organic sales +6.9% (+8.3% ex-COVID testing).
Medical Devices sales +9.9% reported (+12.6% organic); FreeStyle Libre revenue $1.7B.
Full-year 2025 adjusted EPS guidance reaffirmed: $5.05-$5.25; Q2 adj. EPS $1.23-$1.27.
Volt PFA System received CE Mark; TECTONIC IVL pivotal trial initiated in U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.